|Articles|March 15, 2007

Once-daily drug as safe as original formula

Lrvine, CA-ISTA Pharmaceuticals Inc. said its bromfenac sodium ophthalmic solution (Xibrom) once-daily formulation produced highly statistically significant results in its phase III clinical trials.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME